Recent high-throughput genome-wide analyses characterizing the mutational landscape of multiple cancer types have identified inactivating mutations/deletions in UTX that frequently occur in breast cancer, renal cancer, bladder cancer, and leukemia17–19. The gene discussed is KDM6A; the disease is breast carcinoma.